secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001636282-25-000104
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics reports positive Phase 1 data for SPY003 with ~85-day half-life; Q3 net loss $11.2M
--------------------------------------------------------------------------------

- SPY003 Phase 1 interim results show half-life of ~85 days, supporting potential quarterly or twice annual maintenance dosing.
- SPY003 well tolerated, no serious adverse events; safety profile consistent with anti-IL-23 class.
- Q3 2025 net loss of $11.2M, compared to $69.0M in Q3 2024; R&D expenses $45.2M.
- Pro forma cash $782.7M as of Sep 30, 2025, including $296.5M net from October 2025 public offering.
- Company expects 6 proof-of-concept readouts in 2026 from SKYLINE and SKYWAY Phase 2 trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/0001636282-25-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628225000104/syre-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001636282-25-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer